
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9085681/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early Circulating Lymphocyte Apoptosis in Human Septic Shock Is Associated with Poor Outcome. Shock, 2002, 18, 487-494.	1.0	309
2	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 2014, 28, 2367-2375.	3.3	281
3	Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 315-327.	2.5	184
4	Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia, 2012, 26, 1053-1063.	3.3	163
5	Modulation of HLA-G Antigens Expression by Human Cytomegalovirus: Specific Induction in Activated Macrophages Harboring Human Cytomegalovirus Infection. Journal of Immunology, 2000, 164, 6426-6434.	0.4	151
6	Monocyte Human Leukocyte Antigen–DR Transcriptional Downregulation by Cortisol during Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1144-1151.	2.5	143
7	Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis. Leukemia, 2010, 24, 2080-2089.	3.3	133
8	Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood, 2012, 119, 2556-2567.	0.6	133
9	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood, 2016, 128, 1081-1092.	0.6	120
10	DC-SIGN–expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood, 2015, 126, 1911-1920.	0.6	109
11	High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia, 2012, 26, 559-562.	3.3	97
12	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia, 2018, 32, 1261-1265.	3.3	87
13	IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood, 2017, 129, 2507-2518.	0.6	80
14	Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia, 2012, 26, 139-148.	3.3	77
15	Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase. Cancer Research, 2009, 69, 3228-3237.	0.4	76
16	CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-κB Activation and Up-Regulation of c-FLIP and Bcl-xL. Journal of Immunology, 2008, 181, 1001-1011.	0.4	75
17	Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Human Immunology, 2003, 64, 752-761.	1.2	72
18	Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Human Immunology, 2002, 63, 83-90.	1.2	69

#	Article	IF	CITATIONS
19	Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. British Journal of Haematology, 2007, 138, 202-212.	1.2	68
20	Soluble HLA-G molecules are increased in lymphoproliferative disorders. Human Immunology, 2003, 64, 1093-1101.	1.2	65
21	Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. Oncotarget, 2015, 6, 16471-16487.	0.8	60
22	Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Critical Care Medicine, 2006, 34, 1193-1201.	0.4	59
23	HLA-G protein expression is not induced during malignant transformation. Tissue Antigens, 1999, 53, 335-346.	1.0	55
24	Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells, 2020, 38, 146-159.	1.4	50
25	Modulation of HLA-G antigens expression in myelomonocytic cells. Human Immunology, 2000, 61, 1086-1094.	1.2	48
26	Stromal Cell Contribution to Human Follicular Lymphoma Pathogenesis. Frontiers in Immunology, 2012, 3, 280.	2.2	46
27	HLA-G and lymphoproliferative disorders. Seminars in Cancer Biology, 2003, 13, 379-385.	4.3	45
28	Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. Immunity, 2021, 54, 1788-1806.e7.	6.6	43
29	Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. Leukemia, 2017, 31, 988-991.	3.3	41
30	Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules. Journal of Leukocyte Biology, 2004, 76, 1125-1133.	1.5	38
31	COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis. Clinical Cancer Research, 2014, 20, 2663-2673.	3.2	35
32	Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica, 2012, 97, 1686-1694.	1.7	34
33	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. OncoImmunology, 2015, 4, e1026503.	2.1	33
34	Linking the KIR phenotype with <i>STAT3</i> and <i>TET2</i> mutations to identify chronic lymphoproliferative disorders of NK cells. Blood, 2021, 137, 3237-3250.	0.6	32
35	Major histocompatibility complex abnormalities in non-Hodgkin lymphomas. British Journal of Haematology, 2002, 119, 417-424.	1.2	31
36	Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. Journal of Immunology, 2015, 195, 2207-2215.	0.4	26

#	Article	IF	CITATIONS
37	HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood, 2018, 132, 510-520.	0.6	25
38	Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Advances, 2021, 5, 1816-1829.	2.5	22
39	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma. Clinical Cancer Research, 2019, 25, 735-746.	3.2	21
40	Targeting netrinâ€1/ <scp>DCC</scp> interaction in diffuse large Bâ€cell and mantle cell lymphomas. EMBO Molecular Medicine, 2016, 8, 96-104.	3.3	19
41	Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche. Blood, 2021, 138, 57-70.	0.6	19
42	A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival. Blood Advances, 2021, 5, 5372-5386.	2.5	18
43	Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse. Cancers, 2020, 12, 2865.	1.7	14
44	Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. Annals of Oncology, 2016, 27, 1349-1350.	0.6	13
45	The class-specific BCR tonic signal modulates lymphomagenesis in ac-mycderegulation transgenic model. Oncotarget, 2014, 5, 8995-9006.	0.8	10
46	SPONTANEOUS PHENOTYPIC AND MOLECULAR BLOOD REMISSION IN A CASE OF CHRONIC LYMPHOCYTIC LEUKAEMIA. British Journal of Haematology, 1999, 107, 213-214.	1.2	9
47	HLA-G Expression in Guillain-Barré Syndrome Is Associated with Primary Infection with Cytomegalovirus. Viral Immunology, 2004, 17, 123-125.	0.6	9
48	<i>IGHV</i> segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies. Haematologica, 2018, 103, e207-e210.	1.7	9
49	Expression Map of the Human Exome in CD34+ Cells and Blood Cells: Increased Alternative Splicing in Cell Motility and Immune Response Genes. PLoS ONE, 2010, 5, e8990.	1.1	8
50	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2021, 12, 755623.	2.2	5
51	Blood Soluble PD-L1 Protein In Aggressive Diffuse Large B-Cell Lymphoma Impacts patient's Overall Survival. Blood, 2013, 122, 361-361.	0.6	4
52	T-Cell Defect in Diffuse Large B-Cell Lymphomas Involves Expansion of Myeloid Derived Suppressor Cells Expressing IL-10, PD-L1, and S100A12. Blood, 2015, 126, 1478-1478.	0.6	1
53	Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ. Blood, 2014, 124, 1665-1665.	0.6	1
54	CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD. Hematological Oncology, 2019, 37, 370-372.	0.8	0

#	Article	IF	CITATIONS
55	CD40L Modulates TRAIL-Induced Apoptosis in Germinal Center Derived B Cell Lymphomas Blood, 2006, 108, 4630-4630.	0.6	0
56	Whole Blood Transcriptional Profiling of DLBCL At Diagnosis: Evidence of Systemic Changes Altering T-Cell Signaling Pathways. Blood, 2011, 118, 2435-2435.	0.6	0
57	Mesenchymal Stromal Cells Orchestrate Follicular Lymphoma Cell Niche Through the CCL2-Dependent Recruitment and Polarization of Monocytes. Blood, 2011, 118, 1566-1566.	0.6	0
58	Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa. Blood, 2015, 126, 3970-3970.	0.6	0
59	Pan-HDAC Inhibitors May Restore PRDM1 Expression in Follicular Lymphoma. Blood, 2018, 132, 2848-2848.	0.6	0